We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » First Patient Enrolled in Laser Ablation Study
First Patient Enrolled in Laser Ablation Study
February 25, 2008
W.L. Gore & Associates and Spectranetics have begun the VIVA II: SALVAGE trial.
The trial will evaluate the Gore Viabahn endoprosthesis and Spectranetics’ Turbo-Booster and Turbo elite laser catheter with the CVX-300 Excimer laser system for the treatment of peripheral vascular disease in the superficial femoral artery.
The study will evaluate the effectiveness of the combination as a treatment for up to 100 patients with chronic lower-limb ischemia associated with femoro-popliteal in-stent restenosis — a renarrowing or blockage of an artery at a treatment site, Spectranetics said.
